Published in Am J Respir Crit Care Med on October 04, 2007
Cyclic AMP: master regulator of innate immune cell function. Am J Respir Cell Mol Biol (2008) 2.00
Prostaglandin E2 as an inhibitory modulator of fibrogenesis in human lung allografts. Am J Respir Crit Care Med (2012) 1.47
Prostaglandin E2 inhibits specific lung fibroblast functions via selective actions of PKA and Epac-1. Am J Respir Cell Mol Biol (2008) 1.45
Prostaglandin E(2) induces fibroblast apoptosis by modulating multiple survival pathways. FASEB J (2009) 1.41
SPARC suppresses apoptosis of idiopathic pulmonary fibrosis fibroblasts through constitutive activation of beta-catenin. J Biol Chem (2010) 1.29
The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice. J Clin Invest (2010) 1.27
Hypermethylation of PTGER2 confers prostaglandin E2 resistance in fibrotic fibroblasts from humans and mice. Am J Pathol (2010) 1.23
Prostaglandin E2 and the pathogenesis of pulmonary fibrosis. Am J Respir Cell Mol Biol (2011) 1.14
Fibrosis of two: Epithelial cell-fibroblast interactions in pulmonary fibrosis. Biochim Biophys Acta (2013) 1.11
Matrices of physiologic stiffness potently inactivate idiopathic pulmonary fibrosis fibroblasts. Am J Respir Cell Mol Biol (2013) 1.08
A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice. Respir Res (2010) 1.07
Prostaglandin E₂ increases fibroblast gene-specific and global DNA methylation via increased DNA methyltransferase expression. FASEB J (2012) 1.07
Eicosanoid lipid mediators in fibrotic lung diseases: ready for prime time? Chest (2008) 1.04
Increased survivin expression contributes to apoptosis-resistance in IPF fibroblasts. Adv Biosci Biotechnol (2012) 0.98
Airway remodeling in murine asthma correlates with a defect in PGE2 synthesis by lung fibroblasts. Am J Physiol Lung Cell Mol Physiol (2011) 0.96
Histone modifications are responsible for decreased Fas expression and apoptosis resistance in fibrotic lung fibroblasts. Cell Death Dis (2013) 0.92
Reversal of myofibroblast differentiation by prostaglandin E(2). Am J Respir Cell Mol Biol (2013) 0.90
Prostaglandin E2 resistance in granulocytes from patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol (2014) 0.89
Pathogenesis of aspirin-exacerbated respiratory disease and reactions. Immunol Allergy Clin North Am (2012) 0.88
Nickel and the microbial toxin, MALP-2, stimulate proangiogenic mediators from human lung fibroblasts via a HIF-1alpha and COX-2-mediated pathway. Toxicol Sci (2008) 0.88
Lung fibroblasts from patients with idiopathic pulmonary fibrosis exhibit genome-wide differences in DNA methylation compared to fibroblasts from nonfibrotic lung. PLoS One (2014) 0.85
Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2. Eur J Pharm Biopharm (2012) 0.83
Plasmin overcomes resistance to prostaglandin E2 in fibrotic lung fibroblasts by reorganizing protein kinase A signaling. J Biol Chem (2011) 0.81
Beyond TGF-beta: a prostaglandin promotes fibrosis. Nat Med (2009) 0.81
Prostanoids in Asthma and COPD: Actions, Dysregulation, and Therapeutic Opportunities. Chest (2015) 0.81
Prostaglandin E2 inhibits α-smooth muscle actin transcription during myofibroblast differentiation via distinct mechanisms of modulation of serum response factor and myocardin-related transcription factor-A. J Biol Chem (2014) 0.81
Prostaglandin E₂ and polyenylphosphatidylcholine protect against intestinal fibrosis and regulate myofibroblast function. Dig Dis Sci (2015) 0.79
Lung Pericytes and Resident Fibroblasts: Busy Multitaskers. Am J Pathol (2016) 0.79
Normal Human Lung Epithelial Cells Inhibit Transforming Growth Factor-β Induced Myofibroblast Differentiation via Prostaglandin E2. PLoS One (2015) 0.77
Following the path of CCL2 from prostaglandins to periostin in lung fibrosis. Am J Respir Cell Mol Biol (2014) 0.77
Reversal of the Transcriptome by Prostaglandin E2 during Myofibroblast Dedifferentiation. Am J Respir Cell Mol Biol (2016) 0.77
Prostaglandin E₂ and polyenylphosphatidylcholine: stiff competition for the fibrotic complications of inflammatory bowel disease? Dig Dis Sci (2015) 0.75
DNA methylation regulated gene expression in organ fibrosis. Biochim Biophys Acta (2017) 0.75
Wound healing--aiming for perfect skin regeneration. Science (1997) 16.08
Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem (1986) 10.00
Transforming growth factor beta in tissue fibrosis. N Engl J Med (1994) 9.73
Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med (2001) 8.95
Prostanoid receptors: structures, properties, and functions. Physiol Rev (1999) 8.60
Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med (1998) 6.22
Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (1998) 4.88
Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med (2001) 4.01
Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis. Proc Natl Acad Sci U S A (2000) 3.47
The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am J Pathol (1991) 3.35
An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am Rev Respir Dis (1989) 3.12
Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. J Clin Invest (1995) 2.59
Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J (2002) 2.19
Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation. Am J Respir Cell Mol Biol (2003) 2.14
Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice. Am J Pathol (2001) 1.96
Modulation of alveolar macrophage-driven fibroblast proliferation by alternative macrophage mediators. J Clin Invest (1986) 1.82
Heterogeneous proliferative characteristics of human adult lung fibroblast lines and clonally derived fibroblasts from control and fibrotic tissue. Am Rev Respir Dis (1988) 1.68
Prostaglandin E(2) inhibits collagen expression and proliferation in patient-derived normal lung fibroblasts via E prostanoid 2 receptor and cAMP signaling. Am J Physiol Lung Cell Mol Physiol (2006) 1.66
Prostacyclin derivatives prevent the fibrotic response to TGF-beta by inhibiting the Ras/MEK/ERK pathway. FASEB J (2002) 1.64
Severity of lung injury in cyclooxygenase-2-deficient mice is dependent on reduced prostaglandin E(2) production. Am J Pathol (2004) 1.56
Prostaglandin E(2) inhibits fibroblast chemotaxis. Am J Physiol Lung Cell Mol Physiol (2001) 1.55
Prostaglandin E(2) inhibits fibroblast migration by E-prostanoid 2 receptor-mediated increase in PTEN activity. Am J Respir Cell Mol Biol (2004) 1.47
Human alveolar macrophage inhibition of lung fibroblast growth. A prostaglandin-dependent process. Am Rev Respir Dis (1985) 1.45
Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest (2001) 1.39
Bleomycin-induced E prostanoid receptor changes alter fibroblast responses to prostaglandin E2. J Immunol (2005) 1.33
Different expression of TNF-alpha receptors and prostaglandin E(2 )Production in normal and fibrotic lung fibroblasts: potential implications for the evolution of the inflammatory process. Am J Respir Cell Mol Biol (2000) 1.31
Epithelial necrosis and alveolar collapse in the pathogenesis of usual interstitial pneumonia. Chest (1988) 1.23
The differential effect of prostaglandin E2 on transforming growth factor-beta and insulin-induced collagen formation in lung fibroblasts. J Biol Chem (1989) 1.16
Role of EP2 receptors and cAMP in prostaglandin E2 regulated expression of type I collagen alpha1, lysyl oxidase, and cyclooxygenase-1 genes in human embryo lung fibroblasts. J Cell Biochem (1998) 1.09
Proliferative characteristics of fibroblast lines derived from open lung biopsy specimens of patients with IPF (UIP). Chest (1992) 1.02
Normal scarring: importance of myofibroblasts. Wound Repair Regen (2002) 0.95
Expression and regulation of human pulmonary fibroblast-derived monocyte chemotactic peptide-1. Am J Physiol (1992) 0.94
Pathologic features and the classification of interstitial pneumonia of unknown etiology. Bull Chest Dis Res Inst Kyoto Univ (1990) 0.87
Approaches to evaluation of fibrogenic pathways in surgical lung biopsy specimens. Methods Mol Med (2005) 0.84
Fibrotic lung fibroblasts show blunted inhibition by cAMP due to deficient cAMP response element-binding protein phosphorylation. J Pharmacol Exp Ther (2005) 0.84
Overproduction of collagen and diminished SOCS1 expression are causally linked in fibroblasts from idiopathic pulmonary fibrosis. Biochem Biophys Res Commun (2006) 0.84
Discordant regulation of human type I collagen genes by prostaglandin E2. Biochim Biophys Acta (1992) 0.81
When defenses against fibroproliferation fail: spotlight on an axis of prophylaxis. Am J Respir Crit Care Med (2003) 0.79
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2012) 22.96
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med (2014) 10.62
Azithromycin for prevention of exacerbations of COPD. N Engl J Med (2011) 8.66
Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society. Radiology (2012) 6.92
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med (2013) 6.82
Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med (2011) 6.74
Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 6.71
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med (2012) 6.51
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med (2015) 6.03
Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2007) 5.92
The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol (2007) 5.79
Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med (2012) 5.54
Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med (2012) 5.33
The Diesel Exhaust in Miners study: a nested case-control study of lung cancer and diesel exhaust. J Natl Cancer Inst (2012) 5.27
The 2004 World Health Organization classification of lung tumors. Semin Roentgenol (2005) 5.23
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest (2007) 5.17
International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant (2006) 4.95
A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2012) 4.81
The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg (2012) 4.68
Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS One (2011) 4.65
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet (2009) 4.40
Mechanisms of pulmonary fibrosis. Annu Rev Med (2004) 4.37
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet (2009) 4.29
The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med (2005) 4.25
A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med (2010) 4.19
Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med (2010) 4.19
NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med (2009) 4.05
CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol (2005) 4.02
A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med (2016) 3.99
GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med (2012) 3.98
Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med (2008) 3.97
Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol (2011) 3.92
Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. Arch Pathol Lab Med (2010) 3.91
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med (2011) 3.85
Clinical diagnosis of hypersensitivity pneumonitis. Am J Respir Crit Care Med (2003) 3.81
Epigenetic regulation of the alternatively activated macrophage phenotype. Blood (2009) 3.76
Diffuse lung disease in young children: application of a novel classification scheme. Am J Respir Crit Care Med (2007) 3.72
Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology (2005) 3.71
TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events. J Exp Med (2008) 3.62
Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med (2014) 3.51
Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res (2004) 3.43
Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm. Am J Respir Crit Care Med (2012) 3.42
Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology (2011) 3.30
Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol (2008) 3.30
Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med (2003) 3.07
Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med (2002) 3.06
Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med (2008) 3.04
Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med (2004) 2.97
Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med (2012) 2.95
The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol (2015) 2.95
Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10). Am J Respir Crit Care Med (2005) 2.86
Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res (2012) 2.85
Gender and chronic obstructive pulmonary disease: why it matters. Am J Respir Crit Care Med (2007) 2.80
Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med (2003) 2.78
Spirometry utilization for COPD: how do we measure up? Chest (2007) 2.77
Intraoperative frozen section analysis of margins in breast conserving surgery significantly decreases reoperative rates: one-year experience at an ambulatory surgical center. Am J Clin Pathol (2012) 2.73
Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med (2003) 2.71
The role of CCL12 in the recruitment of fibrocytes and lung fibrosis. Am J Respir Cell Mol Biol (2006) 2.68
Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. Am J Respir Crit Care Med (2012) 2.65
Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med (2002) 2.56
Solid cancers after allogeneic hematopoietic cell transplantation. Blood (2008) 2.56
Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg (2006) 2.53
Prostaglandin E2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptor-mediated increase in intracellular cyclic AMP. J Immunol (2004) 2.51
Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med (2012) 2.46
US lung cancer trends by histologic type. Cancer (2014) 2.46
Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2cm or smaller. J Natl Cancer Inst (2013) 2.45
International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 report. J Thorac Oncol (2012) 2.45
Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med (2006) 2.37
Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med (2003) 2.35